All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Constant BCR-ABL transcript level less than or equal 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F10%3A00008261" target="_blank" >RIV/00023736:_____/10:00008261 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Constant BCR-ABL transcript level less than or equal 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

  • Original language description

    This work is dealing with the important question of when should be CML patients screened for BCR-ABL kinase domain mutation. We showed that the expression of BCR-ABL plateau in a minimum of 3 subsequent samples from regular BCR-ABL transcript level monitoring may be a reliable indicator for mutation testing. The BCR-ABL constant levels ?0.1% clearly selected patients in complete cytogenetic remission who did not achieve major molecular response for mutation analysis. This approach reduces the number ofexaminations for mutation analysis and is a cost-effective alternative applicable in clinical practice.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/NR8758" target="_blank" >NR8758: Early markers of resistance to imatinib in chronic myeloid leukemia treatment</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Others

  • Publication year

    2010

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Experimental Hematology

  • ISSN

    0301-472X

  • e-ISSN

  • Volume of the periodical

    38

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

  • UT code for WoS article

    000273142300004

  • EID of the result in the Scopus database